Navigation Links
ThromboGenics NV Announces Business Update and Half Year Results 2009
Date:8/27/2009

66,404 76,093 Unaudited consolidated statement of cash flows ThromboGenics Unaudited consolidated statement of cash flow For the period ended 6 months 6 months Jan 2009 Jan 2008 In '000 Euro, except per share amounts - June 2009 - June 2008 According to IFRS OPERATING ACTIVITIES {Loss} profit for the period (4,663) 18,028 Financial expenses 179 190 Financial income (1,034) (1,022) Depreciation of property, plant and equipment 224 195 Depreciation of intangible assets 1 - Costs of share-based payments 249 304 Cash flows before modification of the working capital (5,044) 1,695 (Increase) / decrease in trade and other receivables including tax receivables (85) (30,703) Increase / (decrease) in short-term liabilities 508 4,884 Net cash flow from operating activities (4,621) (8,124) INVESTING ACTIVITIES Retirement of fixed assets (6) (2) Investments 22,809 (32) Interest received and similar income 894 838 Acquisition of intangible assets (345) (95) Acquisition of property, plant and equipment (4,908) - Net cash (used for) / generated by investment activities 18,444 709 FINANCING ACTIVITIES Income from share issues 3,025
'/>"/>
SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ThromboGenics NV: Business Update
2. ThromboGenics Announces Business Update and 2008 Full Year Results
3. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
4. ThromboGenics N.V.: Business Update
5. ThromboGenics Announces Half Year Results 2008
6. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
7. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
8. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
9. ThromboGenics N.V. - Business Update
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. ThromboGenics Announces 2007 Full Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... July 23, 2014 StemGenex® , ... in the US aimed at improving the lives of ... clinical study for Parkinson’s disease. StemGenex believes that ... cell therapy are paramount when providing care to patients ... makes stem cell therapy accessible to the millions of ...
(Date:7/23/2014)... 2014 - Valentis ... Trendlines Agtech , announced it has signed an ... leading agricultural thermoplastics applications companies. ... combines nanocrystalline cellulose (NCC), a biodegradable, transparent material ... to produce highly improved polymeric films. Used as ...
(Date:7/23/2014)... Iowa (PRWEB) July 23, 2014 DuPont ... the business as vice president of Agricultural Biotechnology (ABT), ... Biotechnology where he served most recently as president, chief ... biotechnology and business leadership in the seed and crop ... said Paul E. Schickler , president of DuPont ...
(Date:7/23/2014)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... announced that the underwriters of its common stock ... an additional 420,000 shares of common stock at ... less underwriting discounts and commissions, in connection with ... shares of common stock, bringing the expected net ...
Breaking Biology Technology:StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3
... Calif., Nov. 7 InterMune, Inc.,(Nasdaq: ITMN ) ... and President of InterMune, will present at Deutsche,Bank,s 2008 ... p.m. EST., To access a live audio webcast ... on to the investor relations page of InterMune,s,corporate website ...
... NeoGenomics, Inc.,(OTC Bulletin Board: NGNM) announced today ... present at the Rodman & Renshaw,10th Annual Healthcare ... New York Palace Hotel in New York City. ... public life sciences and biotech companies.,Gasparini and other ...
... Inc. (OTC,Bulletin Board: AIMM) today reported a net loss of ... three months ended September 30, 2008,compared with a net loss ... the three months ended September 30, 2007. For the nine ... $0.01 per share,basic and diluted, compared with net loss of ...
Cached Biology Technology:NeoGenomics to Present at the Rodman & Renshaw Healthcare Conference on November 10 2AutoImmune Inc. Reports 2008 Third Quarter Financial Results 2AutoImmune Inc. Reports 2008 Third Quarter Financial Results 3
(Date:7/23/2014)... 2014 BCC Research ... GLOBAL MARKETS AND TECHNOLOGIES FOR SENSORS , the global ... grow to nearly $154.4 billion by 2020, with a ... image, flow, and level sensors segment is moving at ... http://photos.prnewswire.com/prnh/20140723/694805 ) , Sensors have become indispensable ...
(Date:7/23/2014)... , July 23, 2014   MedNet Solutions ... in clinical study management systems, is pleased to ... proven life sciences industry executive with over 25 ... Officer (COO).  Clareece will be responsible for MedNet,s ... operational efficiency and quality product/service delivery.  ...
(Date:7/23/2014)... DNA has the nasty habit of getting tangled and ... function and learn how to disentangle them (e.g. useful ... International School for Advanced Studies (SISSA) in Trieste and ... they simulate these knots and their dynamics. In their ... Matter , Micheletti together with Marco Di Stefano, first ...
Breaking Biology News(10 mins):Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 2Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 3MedNet Appoints Clareece West As Chief Operating Officer 2
... Scott & White Healthcare in Temple, Texas, found that a new ... is unique in that it works both by stopping the cancer ... the immune system to destroy breast cancer cells and keeps them ... work in both ways, while all other treatments work in one ...
... , , ... Cotecna,Inspection SA, Philippines received accreditation from the Committee for,Accreditation ... break bulk,surveyor for cargo entering the Philippines. Cotecna is ... by the Philippine government under,their Administrative Order (AO) 243-A ...
... to drape those huge fake spider webs over doorways and ... long-standing mystery about real spider webs: It is the secret ... a new generation of biobased adhesives and glues "green" ... uses. A report on the study was published in ACS, ...
Cached Biology News:Scott & White Healthcare researcher finds success with new anti-cancer drug 2Cotecna Philippines Accredited as Bulk and Break Bulk Surveyor 2
... an 18 amino acid synthetic peptide whose sequences are derived from ... to carboxy terminus): S(21) - S - M - P - ... - A - I - D - K - K - ... This peptide may be used for neutralization and control experiments with ...
... System, Basic Package Superior Protein Detection ... The ProXPRESS 2D Proteomic Imaging System is ... both proteomic and general life science research ... the use of all dyes in the ...
... peptide microarrays designed for quantitative assays ... and built on the flexible and ... of customer specified sequences can be ... provide assistance with custom sequence design. ...
... extended-length microarrays are custom designed to meet ... are available: 8,455 features per array (2 ... features per array (1 array/slide). ... length - This extended length delivers ...
Biology Products: